Specify a stock or a cryptocurrency in the search bar to get a summary
Applied Therapeutics Inc
APLTApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. Address: 545 Fifth Avenue, New York, NY, United States, 10017
Analytics
WallStreet Target Price
7.67 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures APLT
Dividend Analytics APLT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History APLT
Stock Valuation APLT
Financials APLT
Results | 2019 | Dynamics |